The composition based on the molecular subtypes of BC was as follows: 63% (33/65) patients were classified as luminal A, 25% (13/65) patients were luminal B, 7.7% (4/65) patients were HER2 positive and 3.8% (2/65) were triple-negative cancers (TNC). Here, ERBB2 is linked to breast cancer.